Development of an Atherogenic Metabolic Risk Factor Profile Associated With the Use of Atypical Antipsychotics. James L. Karagianis and Eduardo Dunayevich

View This PDF

NB: This article is only available as a PDF.

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We read with interest the article by Alméras et al.1 reporting a worse metabolic risk profile in olanzapine-treated patients compared with risperidone-treated patients and a control group. While we agree with the authors on the need for research on this important topic, we believe the serious limitations to the methodology employed in this study significantly limit the interpretation and generalizability of their findings. First, the nonrandomized, cross-sectional design introduces likely bias in the selection of patients assigned to risperidone and olanzapine.​

J Clin Psychiatry 2005;66(1):137-137